Steven P. James

Steven James has over 35 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Mr. James was most recently president and Chief Executive Officer and director of Pionyr Immunotherapeutics until its acquisition by Ikena Oncology. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, and Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve is currently a director of Allakos Inc. and Lyterian Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).